IMUX

Immunic Inc

Add to Watchlist

Advanced Chart

1.120

+0.05(4.673%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.130

Open

1.080

VWAP

1.09

Vol

989.08K

Mkt Cap

107.32M

Low

1.040

Amount

1.07M

EV/EBITDA(TTM)

Total Shares

90.08M

93.01M

EV/OCF(TTM)

P/S(TTM)

Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.153

-38.67%

-0.157

-34.72%

-0.158

-24.6%

Estimates Revision

The market is revising No Change the revenue expectations for Immunic, Inc. (IMUX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 0.00%.

EPS Estimates for FY2025

Revise Downward

-8.47%

In Past 3 Month

Stock Price

No Change

0.00%

In Past 3 Month

5 Analyst Rating

815.18% Upside

Wall Street analysts forecast IMUX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMUX is 10.25 USD with a low forecast of 4.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

815.18% Upside

Current: 1.120

Low

4.00

Averages

10.25

High

22.00

815.18% Upside

Current: 1.120

Low

4.00

Averages

10.25

High

22.00

B. Riley

William Wood

Buy

downgrade

$6 -> $5

2025-05-23

Reason

B. Riley

William Wood

Price Target

$6 -> $5

2025-05-23

downgrade

Buy

Reason

B. Riley analyst William Wood lowered the firm's price target on Immunic to $5 from $6 and keeps a Buy rating on the shares. The firm updated the company's model post the Q1 report. Riley factored in the prospects of a likely near-term strategic financing to extend Immunic's cash runway well beyond 2026.

B. Riley Securities

William Woods

Strong Buy

Reiterates

2025-04-16

Reason

B. Riley Securities

William Woods

Price Target

2025-04-16

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Reiterates

$10

2025-04-15

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$10

2025-04-15

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$17

2025-04-10

Reason

D. Boral Capital

Jason Kolbert

Price Target

$17

2025-04-10

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$17

2025-04-01

Reason

D. Boral Capital

Jason Kolbert

Price Target

$17

2025-04-01

Maintains

Strong Buy

Reason

William Blair

Myles Minter

Buy

Initiates

n/a

2025-03-25

Reason

William Blair

Myles Minter

Price Target

n/a

2025-03-25

Initiates

Buy

Reason

William Blair initiated coverage of Immunic with an Outperform rating and $6.80 fair value estimate. Immunic is a late-stage clinical company developing lead asset vidofludimus calcium for multiple sclerosis, the analyst tells investors in a research note. The firm believes vidofludimus could command market share as an oral therapy in a market projected to surpass $45B in 2033. It thinks vidofludimus calcium's opportunity in relapse-remitting MS along can support Immunic's share outperformance.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Immunic Inc (IMUX.O) is -1.74, compared to its 5-year average forward P/E of -2.43. For a more detailed relative valuation and DCF analysis to assess Immunic Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.43

Current PE

-1.74

Overvalued PE

-0.52

Undervalued PE

-4.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

10.53

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

89.79

Undervalued EV/EBITDA

-68.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1207.72

Current PS

0.00

Overvalued PS

4749.35

Undervalued PS

-2333.92

Financials

Annual

Quarterly

FY2025Q1

YoY :

+12.33%

-26.83M

Operating Profit

FY2025Q1

YoY :

-13.90%

-25.47M

Net Income after Tax

FY2025Q1

YoY :

-16.67%

-0.25

EPS - Diluted

FY2025Q1

YoY :

-9.07%

-21.82M

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

70.2K

USD

Months

3-6

0.0

USD

Months

6-9

100.4K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

3.5M

Volume

6-9

Months

2.0M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

70.2K

USD

Months

3-6

0.0

USD

Months

6-9

100.4K

USD

Months

0-12

0.0

USD

Months

IMUX News & Events

Events Timeline

2025-06-05 (ET)

2025-06-05

07:41:20

Immunic announces vidofludimus calcium trial data

2025-06-05

07:04:00

Immunic completes enrollment for both ENSURE trials

2025-05-29 (ET)

2025-05-29

09:13:34

Immunic price target lowered to $10 from $17 at D. Boral Capital

News

9.0

06-24NASDAQ.COM

Immunic Posts Positive Long-Term OLE Data From Phase 2 Trial Of Vidofludimus Calcium In RRMS

9.0

06-24Newsfilter

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

5.0

06-06NASDAQ.COM

Insider Purchase: CEO and Director of $IMUX Buys 15,000 Shares